Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.42 |
| ▸ | MMP13 | P45452 | 3/20 | 0.42 |
| ▸ | MMP1 | P03956 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 5/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7123531 | 1.00 | MMP2 (0.42) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7128712 | 0.84 | MMP2 (0.38) | MMP2MMP13MMP9MMP8CA2 | |
| SCHEMBL7128722 | 0.84 | MMP2 (0.38) | MMP2MMP13MMP9MMP8CA2 | |
| SCHEMBL7128718 | 0.84 | MMP2 (0.38) | MMP2MMP13MMP9MMP8CA2 | |
| SCHEMBL7123678 | 0.81 | MMP2 (0.44) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7123675 | 0.81 | MMP2 (0.44) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7114248 | 0.75 | MMP2 (0.41) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7124781 | 0.75 | MMP2 (0.43) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7114256 | 0.75 | MMP2 (0.41) | MMP2MMP13MMP1MMP9MMP8 | |
| SCHEMBL7124787 | 0.75 | MMP2 (0.43) | MMP2MMP13MMP1MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | MMP2 1392/4885MMP13 335/4885MMP1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.